Cargando…

Berbamine inhibits RANKL- and M-CSF-mediated osteoclastogenesis and alleviates ovariectomy-induced bone loss

Osteoporosis is a common public health problem characterized by decreased bone mass, increased bone brittleness and damage to the bone microstructure. Excessive bone resorption by osteoclasts is the main target of the currently used drugs or treatment for osteoporosis. Effective antiresorptive drugs...

Descripción completa

Detalles Bibliográficos
Autores principales: Qi, Guobin, Jiang, Zengxin, Lu, Wei, Li, Defang, Chen, Weibing, Yang, Xiuying, Ding, Lei, Yuan, Hengfeng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9666778/
https://www.ncbi.nlm.nih.gov/pubmed/36408260
http://dx.doi.org/10.3389/fphar.2022.1032866
_version_ 1784831585318600704
author Qi, Guobin
Jiang, Zengxin
Lu, Wei
Li, Defang
Chen, Weibing
Yang, Xiuying
Ding, Lei
Yuan, Hengfeng
author_facet Qi, Guobin
Jiang, Zengxin
Lu, Wei
Li, Defang
Chen, Weibing
Yang, Xiuying
Ding, Lei
Yuan, Hengfeng
author_sort Qi, Guobin
collection PubMed
description Osteoporosis is a common public health problem characterized by decreased bone mass, increased bone brittleness and damage to the bone microstructure. Excessive bone resorption by osteoclasts is the main target of the currently used drugs or treatment for osteoporosis. Effective antiresorptive drugs without side effects following long-term administration have become a major focus of anti-osteoporotic drugs. In the present study, we investigated the effect of berbamine, a small molecule natural product from Berberis amurensis Rupr, a traditional Chinese medicine, on RANKL-induced osteoclast differentiation in vitro and ovariectomy-induced bone loss in vivo. The results demonstrated that berbamine at a safe and effective dose inhibited osteoclastogenesis and bone resorption function in vitro by suppressing the nuclear factor-κB signaling pathway. In addition, berbamine protected against osteoporosis by inhibiting osteoclastogenesis and bone resorption function without affecting osteogenesis in the ovariectomy mouse model. These findings revealed that berbamine has a protective role against osteoporosis and may represent a novel promising treatment strategy for osteoporosis.
format Online
Article
Text
id pubmed-9666778
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-96667782022-11-17 Berbamine inhibits RANKL- and M-CSF-mediated osteoclastogenesis and alleviates ovariectomy-induced bone loss Qi, Guobin Jiang, Zengxin Lu, Wei Li, Defang Chen, Weibing Yang, Xiuying Ding, Lei Yuan, Hengfeng Front Pharmacol Pharmacology Osteoporosis is a common public health problem characterized by decreased bone mass, increased bone brittleness and damage to the bone microstructure. Excessive bone resorption by osteoclasts is the main target of the currently used drugs or treatment for osteoporosis. Effective antiresorptive drugs without side effects following long-term administration have become a major focus of anti-osteoporotic drugs. In the present study, we investigated the effect of berbamine, a small molecule natural product from Berberis amurensis Rupr, a traditional Chinese medicine, on RANKL-induced osteoclast differentiation in vitro and ovariectomy-induced bone loss in vivo. The results demonstrated that berbamine at a safe and effective dose inhibited osteoclastogenesis and bone resorption function in vitro by suppressing the nuclear factor-κB signaling pathway. In addition, berbamine protected against osteoporosis by inhibiting osteoclastogenesis and bone resorption function without affecting osteogenesis in the ovariectomy mouse model. These findings revealed that berbamine has a protective role against osteoporosis and may represent a novel promising treatment strategy for osteoporosis. Frontiers Media S.A. 2022-11-02 /pmc/articles/PMC9666778/ /pubmed/36408260 http://dx.doi.org/10.3389/fphar.2022.1032866 Text en Copyright © 2022 Qi, Jiang, Lu, Li, Chen, Yang, Ding and Yuan. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Pharmacology
Qi, Guobin
Jiang, Zengxin
Lu, Wei
Li, Defang
Chen, Weibing
Yang, Xiuying
Ding, Lei
Yuan, Hengfeng
Berbamine inhibits RANKL- and M-CSF-mediated osteoclastogenesis and alleviates ovariectomy-induced bone loss
title Berbamine inhibits RANKL- and M-CSF-mediated osteoclastogenesis and alleviates ovariectomy-induced bone loss
title_full Berbamine inhibits RANKL- and M-CSF-mediated osteoclastogenesis and alleviates ovariectomy-induced bone loss
title_fullStr Berbamine inhibits RANKL- and M-CSF-mediated osteoclastogenesis and alleviates ovariectomy-induced bone loss
title_full_unstemmed Berbamine inhibits RANKL- and M-CSF-mediated osteoclastogenesis and alleviates ovariectomy-induced bone loss
title_short Berbamine inhibits RANKL- and M-CSF-mediated osteoclastogenesis and alleviates ovariectomy-induced bone loss
title_sort berbamine inhibits rankl- and m-csf-mediated osteoclastogenesis and alleviates ovariectomy-induced bone loss
topic Pharmacology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9666778/
https://www.ncbi.nlm.nih.gov/pubmed/36408260
http://dx.doi.org/10.3389/fphar.2022.1032866
work_keys_str_mv AT qiguobin berbamineinhibitsranklandmcsfmediatedosteoclastogenesisandalleviatesovariectomyinducedboneloss
AT jiangzengxin berbamineinhibitsranklandmcsfmediatedosteoclastogenesisandalleviatesovariectomyinducedboneloss
AT luwei berbamineinhibitsranklandmcsfmediatedosteoclastogenesisandalleviatesovariectomyinducedboneloss
AT lidefang berbamineinhibitsranklandmcsfmediatedosteoclastogenesisandalleviatesovariectomyinducedboneloss
AT chenweibing berbamineinhibitsranklandmcsfmediatedosteoclastogenesisandalleviatesovariectomyinducedboneloss
AT yangxiuying berbamineinhibitsranklandmcsfmediatedosteoclastogenesisandalleviatesovariectomyinducedboneloss
AT dinglei berbamineinhibitsranklandmcsfmediatedosteoclastogenesisandalleviatesovariectomyinducedboneloss
AT yuanhengfeng berbamineinhibitsranklandmcsfmediatedosteoclastogenesisandalleviatesovariectomyinducedboneloss